Robust NGS Workflow Provides Full BRCA 1/2 Screening
March 13, 2018 The team at Devyser were excited to see our products put to use in a recent research project from Italy, affirming its application in both research and diagnostic applications.
The team at Devyser were excited to see our products put to use in a recent research project, affirming its application in both research and diagnostic applications. “A comprehensive BRCA1/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis”, published in Clinica Chimica Acta 480 by an Italian research team (Concolino, Rizza, Mignone et al) investigated the ability of Next Generation Sequencing (NGS) to function as the primary method for detection of BRCA1/2 Large Genomic Rearrangements (LGRs).
Comprehensive testing of LGRs has been in wide use since 2006, however the most commonly used technique, multiplex ligation-dependent probe amplification (MLPA) has limitations when a great number of samples need to be processed in a short time. Today, many diagnostics laboratories use NGS-based platforms as their main technology for clinical testing, however reliable CNV (Copy Number Variation) information has remained a challenge for NGS-based technologies.
The purpose of this study was to validate a workflow involving the Devyser BRCA panel, Illumina MiSeq platform and the Amplicon Suite software (SmartSeq) for CNV detection in BRCA 1/2 genes.
In comparison to MLPA and MAQ testing, the study found that an integrative approach using NGS was able to detect all present pathogenic LGRs affecting BRCA 1/2 genes, while reducing the time and effort required for CNV analysis.
The paper concludes that: “The workflow represents a robust and easy-to-use-method for full BRCA1/2 screening, which can be easily implemented in routine diagnostic testing.”
New Devyser BRCA NGS study published
In this study, the Devyser BRCA test was used to analyse 227 patient DNA samples.
They concluded that 100% of the expected SNVs and CNVs were detected and that the single-tube PCR-based library preparation format of the kit offers a decrease in processing time as well as a reduced risk of cross-contamination.
New Career opportunities @Devyser
Treffen Sie uns auf der BVDH-Tagung in Köln
November 7, 2017 Treffen Sie uns auf der BVDH-Tagung in Köln, am 17. und 18. November 2017. Besuchen Sie unseren Messestand und erfahren Sie mehr über unsere neuen Produkte z. B. für FH, BRCA and CFTR. Um vorab einen Termin mit unserem Team zu vereinbaren, senden Sie eine Email an: firstname.lastname@example.org
B. für FH, BRCA and CFTR. Um vorab einen Termin mit unserem Team zu vereinbaren, senden Sie eine Email an: email@example.com
Meet Devyser at APCHG2017 in Bangkok
November 2, 2017 Come see us at the 12th APCHG meeting in Bangkok, Thailand on November 8-10. Visit us at booth 15 to see our products for rapid prenatal aneuploidy and NGS kits for BRCA, Familial hypercholesterolemia and CFTR. To schedule a meeting with the Devyser team in advance, please email firstname.lastname@example.org or use the contact form
To schedule a meeting with the Devyser team in advance, please email email@example.com or use the contact form
DEVYSER AND DAHUI BIOTECH SIGN DISTRIBUTION DEAL FOR THE CHINESE MARKET
October 3, 2017 Devyser, pioneer in diagnostic kits for complex DNA testing, and Dahui Biotech, major supplier of biotech and diagnostic products, announce today the signing of a new partnership for distribution of Devyser’s market leading test kits for rapid prenatal aneuploidy diagnostics in China.
Devyser, pioneer in diagnostic kits for complex DNA testing, and Dahui Biotech, major supplier of biotech and diagnostic products, announce today the signing of a new partnership for distribution of Devyser’s market leading test kits for rapid prenatal aneuploidy diagnostics in China.
Ulf Klangby, CEO and founding partner of Devyser, says, “There is an increasing demand for our prenatal diagnostic products in China. Dahui Biotech’s established distribution and service organization reaches genetic laboratories across China. This, together with their extensive expertise in prenatal diagnostic products, makes Dahui Biotech the ideal distribution partner for our products.”
Cheng Zhang, CEO of Dahui Biotech, comments, “We are excited to offer Devyser’s popular prenatal diagnostic products in China. The products are already in use at several reference laboratories in China and are in demand because of their high quality. They help laboratories speed up analysis time from weeks to hours, thereby improving throughput and reducing parental anxiety through shorter waiting time. This is fully in line with our commitment to always offer the best available technology to our customers.”
Devyser utser Ernst Westman till ny styrelseordförande
September 27, 2017 Med lång internationell erfarenhet av både diagnostik- och life scienceindustri är det en starkt meriterad industrialist som valts till ny styrelseordförande i Devyser Holding AB. Ernst Westman är civilingenjör i kemiteknik med specialisering inom medicinsk molekylärbiologi.
Han grundade Boule Diagnostics 1994 och var VD och koncernchef till 31 mars 2017. Boule Diagnostics är idag världsledande inom decentraliserad blodcellräkning och bolagets aktie är noterad på Nasdaq Stockholm.
”Devyser är ett innovativt företag i en snabbt växande bransch av stor betydelse för utveckling av bättre medicinsk diagnostik, där det finns stora möjligheter för svensk ingenjörstradition och kvalitetstänkande. Jag ser verkligen fram emot att bidra till en fortsatt global expansion av Devyser, som redan framgångsrikt sålt sina produkter i mer än 50 länder.” säger Ernst Westman.
“För ett tillväxtbolag som Devyser är det en stor tillgång att ha en ordförande med lång, praktisk erfarenhet av att bygga framgångsrika företag. Ernst har dessutom gedigen branscherfarenhet och passar därmed perfekt för rollen. Han kommer in i en intensiv period där vi bland annat startat flera dotterbolag utomlands och intensifierat vårt engagemang på den kinesiska diagnostikmarknaden. Jag ser fram emot att jobba tillsammans med Ernst och övriga styrelseledamöter för att ta Devyser till nästa nivå” säger Ulf Klangby, VD Devyser.
Sign up for protocol and software updates
Come see us at the AMP GLOBAL 2017 in Berlin
March 29, 2017 Come see us at the AMP GLOBAL 2017 Global Congress on Molecular Pathology, April 3-5, 2017. Visit us at booth 33 to find out more about our latest products for routine diagnostics, including NGS kits for CFTR, BRCA1 and BRCA2.
We look forward to seeing you at Estrel – Congress & Exhibition Center, Berlin, Germany. To schedule a meeting with the Devyser team, please email amp2017(a)devyser.com or complete our contact form at: www.devyser.com/amp2017
Meet us at GfH 2017 in Bochum
March 28, 2017 Come meet us at the 28th Annual Meeting of the Deutsche gesellschaft für humangenetik (gfh) in Bochum, Germany on March 29 – 31. Visit us at booth 41 to see our new products for routine diagnostics, including NGS kits for CFTR and BRCA1 and BRCA2.
To schedule a meeting with the Devyser team, please send an email to firstname.lastname@example.org or complete our contact form at: www.devyser.com/gfh2017
NGS has never been easier!
March 20, 2017 NGS has never been easier – watch how it’s done here
When we launched products based on NGS technology, we had the requirements of the routine diagnostics lab in mind.
In order to take NGS from the research laboratory environment, we had to make our technology fast, reproducible and easy to use. Watch this video to see how you can leverage NGS technology to detect all mutations in the target genes; perform library prep without sample splitting and reduce hands-on time from days to minutes to significantly increase throughput.
We need more talented colleagues!
Visit us at the XIX SIGU meeting in Torino
November 24, 2016 Welcome to visit our booth and our workshop on Friday the 25th of November at the XIX Congresso Nationale SIGU in Torino, Italy.
Welcome to visit our booth and our workshop on Friday the 25th of November at the XIX Congresso Nationale SIGU in Torino, Italy.
The workshop will take place in Sala Madrid 13.30-14.30.
Dr. Claudia Centrone (Firenze) will present a clinical study using our CFTR NGS library kit entitled: "Devyser CFTR, valutazione di un kit NGS per l’analisi del gene CFTR"
Dr. Gabriele Capone and Dr.ssa Laura Papi will present a clinical study using our BRCA NGS library kit entitled: "Devyser BRCA: un nuovo kit NGS per l'identificazione di SNV e CNV nei geni BRCA1 e BRCA2"
Devyser opens subsidiary in Germany
November 8, 2016 Devyser announces the opening of Devyser GmbH near Frankfurt, Germany, to strengthen its local presence. Serving the German, Austrian and Swiss markets where Devyser has experienced strong growth in recent years.
Devyser announces the opening of Devyser GmbH near Frankfurt, Germany, to strengthen its local presence. Serving the German, Austrian and Swiss markets where Devyser has experienced strong growth in recent years.
Download the full pressrelease using this link
JSI develops customized software plug-in for Devyser’s new NGS products
November 1, 2016 Joint solution for in-house processing of next-generation sequencing (NGS) data
Devyser and JSI Medical Systems announce a joint solution for in-house processing of next-generation sequencing (NGS) data. The software platform provided by JSI has a newly developed plug-in that is compatible with all Devyser NGS products, including Devyser BRCA and Devyser CFTR. The solution is now available for all customers using the JSI SEQUENCE Pilot platform, comprising more than 400 installations worldwide. In addition, Devyser will be able to offer installation of SEQUENCE Pilot to its own customers that have in-house analysis capability.
This joint solution will simplify and streamline the diagnostic process for clinicians in hospitals and laboratories, enabling targeted therapies that benefit patients within oncology and hereditary diseases.
Ulf Klangby, CEO and co-founder of Devyser, says, “Being able to offer our NGS kits to users of JSI’s software platform is a fantastic opportunity for us. JSI’s reputation of being at the forefront of bio-informatic platform development is completely aligned with our own philosophy of meeting the needs of the routine diagnostic lab, in this case those with full analytic capacity in-house.”
Joachim Strub, CEO of JSI Medical Systems, comments, “We are excited to enable a robust NGS solution together with Devyser. This will empower our customers and future users of the JSI platform to maintain full control of their analytical processes and results using the latest NGS technology.”
Download the full pressrelease by clicking here
Devyser and Sophia Genetics partner to simplify routine diagnostics using next-generation DNA sequencing
August 30, 2016 Devyser, pioneer in diagnostic kits for complex DNA testing and Sophia Genetics, global leader in Data-Driven Medicine, announce today the signing of a new partnership to simplify the adoption of Next-Generation DNA Sequencing (NGS) for routine diagnostic laboratories.
Devyser, pioneer in diagnostic kits for complex DNA testing and Sophia Genetics, global leader in Data-Driven Medicine, announce today the signing of a new partnership to simplify the adoption of Next-Generation DNA Sequencing (NGS) for routine diagnostic laboratories. Under the terms of the agreement, Sophia Genetics’ advanced analytical platform, Sophia DDM®, will support Devyser’s NGS diagnostic kits for hereditary breast cancer (Devyser BRCA) and cystic fibrosis (Devyser CFTR).
Ulf Klangby, CEO and co-founder of Devyser, says, “We are very excited to offer NGS technology that has the capacity to revolutionize genetic testing. This solution will relieve laboratories from the burden of labor-intensive and complex workflows so that they can really focus on diagnostics. Our partnership will help continue to reduce the diagnostic turnaround time from days to hours, enabling laboratories to significantly improve their efficiency and cut costs.”
Jurgi Camblong, CEO and founder of Sophia Genetics, comments, “We are very pleased to broaden the choice of NGS kits supported by Sophia DDM®. Our fast-growing clinical genomics community will be able to leverage Devyser’s reliable and easy-to-use products to obtain clinical grade results on Sophia DDM®. This partnership continues to help laboratories unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients.”
Sophia Genetics’ and Devyser’s joint effort will immediately be launched worldwide to help routine diagnostic laboratories transition to NGS and obtain improved throughput, reduced hands-on time and trusted results. The solutions will be available through Devyser’s distribution network and to the more than 170 member hospitals of the Sophia DDM® clinical genomics community.
Download the full pressrelease here: Devyser@mynewsdesk
Check out our new careers site!
July 1, 2016 Are you up for the challenge?
Check out our new careers page using this link
Currently we are recruiting:
- Marketing Manager
- Development Scientists
- Field Application Specialist, Sequencing
- Produktionstekniker/medarbetare till vår produktionsavdelning
Welcome to submit your application directly from our careers page
Visit us at SEABCS in Hue City, Vietnam
June 23, 2016 Welcome to visit our booth at the SEABCS in Hue City, Vietnam
Welcome to visit us in our booth at the Southeast Asia Breast Cancer Symposium (http://www.seabcs.org/) in Hue City, Vietnam 24-26 June.
Our Technical Executive manager, Ms. Sandra Kazemi, will be presenting the new Devyser BRCA product during session 3 (12.45) on the 25 June.
Genomeweb covers Devyser’s latest developments
Visit us at the ECFS in Basel
June 8, 2016 Visit us at the ECFS meeting in Basel 8-11 June
Are you visiting the European Cystic Fibrosis Society (ECFS) meeting in Basel, 8-11 June? Please drop by our booth (#5) to learn more about our new NGS product for CFTR diagnostics.
Visit us at ESHG 2016 in Barcelona
May 17, 2016 Visiting ESHG 2016 in Barcelona, 21-24 May?
Please stop by our booth (#470) to learn more about our new NGS products.
New board members appointed
May 5, 2016 Devyser Holding AB announced at its Annual General Meeting yesterday the appointment of two new Board members, Ernst Westman and Lars Höckenström.
Devyser Holding AB announced at its Annual General Meeting yesterday the appointment of two new Board members, Ernst Westman and Lars Höckenström.
Ernst Westman is CEO of the Boule Diagnostics Group since 22 years. Lars Höckenström is currently a senior adviser at Stockholm Corporate Finance. Chairman of the Board Mia Arnhult comments, “I am delighted to have Ernst Westman and Lars Höckenström on Devyser’s Board. Their combined experience and expertise within both the diagnostics industry and finance will greatly benefit our work.”
Devyser at GfH 2016 in Lübeck
March 16, 2016 Interesting first day at the GfH 2016 in Lübeck.
New Devyser AZF v2 and AZF Extension kits now available
January 25, 2016 Devyser is happy to announce the release of the updated Devyser AZF v2 kit and the brand new Devyser AZF Extension kit.
Both products are fully compliant with the revised EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions. The new kits kit include all EAA/EMQN recommended markers for AZF microdeletion screening and extension analysis. A full overview of the markers included in the Devyser AZF v2 and Devyser AZF Extension kits can be found on our website using the attached link and then selecting the download tab.
Devyser at WCRPL in Cannes
January 14, 2016 Exiting first day at the World Congress on Recurrent Pregnancy Loss (WCRPL) in Cannes, France.
New booklets on "Aneuploidy analysis in Pregnancy Loss Samples" by Helen White and "QF-PCR for prenatal Aneuploidy analysis" by Kathy Mann are available in our booth. Please stop by our booth to get your copy!
Devyser raises 15 MSEK in funding
December 15, 2015 Devyser raises 15 MSEK ($1,8M) in funding to support the launch of new cancer diagnostic products
Devyser has raised 15MSEK ($1,8M) in funding to support the launch of new cancer diagnostic products in 2016. Funds were raised from current shareholders and a development loan from the Swedish regional development agency ALMI.
The first product scheduled for release allows complete sequencing of the BRCA1 and BRCA2 genes to help guide treatment of patients with breast and ovarian cancers carrying BRCA-mutations.
“NGS technology has the capacity to revolutionize genetic testing, but uptake has been hindered by labor-intensive and complex workflows up until now” says Ulf Klangby, CEO and co-founder of Devyser. “We are excited to introduce a pioneering NGS product suited for routine diagnostics. Fast to implement and easy to use, Devyser’s proprietary technology reduces the hands-on time from days to hours, allowing laboratories to significantly improve efficiency and cut costs.”
Other Devyser products scheduled for launch in 2016 include additional cancer diagnostic products and a genetic test for complete sequencing of the CFTR gene used in the diagnosis of Cystic Fibrosis.